- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Media Contact
Leverkusen, December 2016 – The latest edition of research, the Bayer scientific magazine, showcases current topics in medical and agricultural research. The cover story "New approaches in crop research" deals with the problem of herbicide-resistant weeds. There are now 250 herbicide-resistant weed species worldwide. These weeds compete with crops for nutrients, water and light, thus reducing yields. Bayer is cooperating with the start-up company Targenomix in the search for new herbicidal active ingredients. Using so-called omics technologies, these scientists are working to understand what happens in plant cells when they are treated with a specific active molecule.
Reading genes for better therapies: every human is unique. That is why an interdisciplinary team from Bayer is conducting computer-supported genome analyses to search for the genetic causes of cardiovascular diseases. Read the latest edition of research, the Bayer scientific magazine, to find out how the researchers plan to leverage this knowledge to the benefit of patients.
The dossier also explains how supercomputers and the analysis of huge data volumes are changing medicine. research presents five projects in which Bayer experts from the most varied of departments in the company’s Pharmaceuticals Division are employing digital technologies and big data analyses: from a pan-European assessment of up to 50,000 anonymized patient data sets for new approaches in cancer therapy through to opportunities for using social media posts to increase drug safety. Experts also explain how important it is to protect data and make sure that big data analyses are backed up by a sound legal framework.
Big data analysis is also an issue of increasing importance for modern and sustainable agriculture. Bayer is working on new digital solutions for higher yields and an even more targeted and efficient use of crop protection products.
Bayer's science magazine features stories researched using journalistic criteria and selected to illustrate how research can improve the lives of humans, animals and plants – fully in keeping with the company's mission, "Bayer: Science For A Better Life". The texts are designed to appeal to the reader with explanatory illustrations, attractive photo galleries showing life in the laboratory and out in the field, and interviews with renowned international scientists. They make the approaches and technologies being used today even more accessible.
research, the Bayer scientific magazine, can be ordered free of charge online at www.bayer.de/de/research.aspx, by phone (+49 214/30-57546), fax (+49 214/30-57547) or e-mail (email@example.com).
The online edition of research: bringing science to life
Bayer's science magazine research is also available online. Go to www.research.bayer.com and immerse yourself in the world of research at Bayer. Fascinating animated sequences, videos and numerous photo galleries make science accessible and comprehensible.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.